RAS(ON) inhibitor doubles median overall survival in patients with metastatic pancreatic cancer
Medical Xpress - medical research advances and health news [Uno…
June 1, 2026
A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to chemotherapy as second-line therapy for patients with metastatic pancreatic cancer.
Discussion in the ATmosphere